This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 14 - 17, 2025
Marriott Marquis San DiegoLive In-Person Event: December 14 - 17, 2025

Diane Hollenbaugh, PhD
Chief Scientific Officer at Bonum Therapeutics
Speaker

Profile

Diane Hollenbaugh is a drug discovery scientist with experience in biologicals research and discovery, and early development. She joined Good Therapeutics in 2019 and transitioned to Bonum Therapeutics following the acquisition by Roche in 2022. Prior to Good, she was Executive Director, Immuno-oncology Discovery at AbbVie where she oversaw the growth of IO efforts. Prior to AbbVie, she has experience at multiple large and small companies, including BMS, Medarex, FivePrime Therapeutics and Schering-Plough/Merck.

She received her PhD from the California Institute of Technology Division of Chemistry and Chemical Engineering following her BS in Chemistry from the University of Washington.

Agenda Sessions

  • Conditional Protein Therapeutics using Dual-Binding Antibodies

    10:30am